Monitor for any future conversion to Schedule 13D if BofA's intent changes, but the passive certification and small incremental increase suggest routine portfolio management. No immediate trading catalyst.
Price Chart
Executive Summary
Bank of America Corp filed an amended Schedule 13G for CytomX Therapeutics, disclosing a passive stake of 11,867,012 shares (5.4% of shares outstanding) as of September 30, 2026. This is an increase from the prior filing (August 3, 2026) where BofA reported a 5.0% stake, representing a modest addition of approximately 0.4 percentage points. The filing is a routine passive ownership update with no indication of activist intent.
Key Financial Metrics
Key Facts
- Bank of America Corp reported beneficial ownership of 11,867,012 shares of CytomX Therapeutics common stock as of September 30, 2026.
- The stake represents 5.4% of the 217,899,284 shares outstanding (based on the issuer's Form 10-Q filed August 6, 2026).
- This is an amendment to a prior Schedule 13G filed August 3, 2026, showing a slight increase in ownership.
- The filing certifies the securities were acquired and are held in the ordinary course of business, not with the purpose of changing or influencing control.
Financial Impact
No material financial impact; stake value approximately $26 million based on market cap of $485M and 5.4% ownership.
Risk Factors
- No material risks identified from this routine passive stake amendment.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| SC 13G/A Filing (Primary) | 0000070858-26-000528 |
| Document: 0000070858-26-000528-index.html | 0000070858-26-000528 |
| Document: 0000070858-26-000528.txt | 0000070858-26-000528 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 28, 2026 1d ago | SC 13G/A | $2.36 | awaiting T+60 | awaiting T+60 | $2.29 (−2.97%) |
Sep 22, 2026 5w ago | Institutional Cluster | $2.94 | awaiting T+60 | awaiting T+60 | $2.29 (−22.11%) |
Jun 22, 2026 18w ago | 8-K | $3.15 $2.77 | ▼ −12.22% | ▼ −15.47% | $2.29 (−27.30%) |
Mar 17, 2026 32w ago | Press Release | $4.40 $2.98 | ▼ −32.27% | ▼ −43.80% | $2.29 (−47.95%) |
Mar 16, 2026 32w ago | Press Release | $5.45 $2.98 | ▲ +45.32% | ▲ +55.18% | $2.29 (+57.98%) |
Mar 16, 2026 32w ago | Press Release | $6.75 $2.94 | ▼ −56.44% | ▼ −66.93% | $2.29 (−66.07%) |
Mar 4, 2026 34w ago | Press Release | $5.07 $3.71 | ▼ −26.82% | ▼ −36.91% | $2.29 (−54.83%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers